• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Biohaven Ltd.

    7/8/26 5:44:00 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BHVN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    BIOHAVEN LTD.

    (Name of Issuer)


    Common Shares

    (Title of Class of Securities)




    G1110E107

    (CUSIP Number)
    06/30/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    G1110E107


    1Names of Reporting Persons

    JANUS HENDERSON GROUP Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,584,676.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,584,676.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,584,676.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.7 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    BIOHAVEN LTD.
    (b)Address of issuer's principal executive offices:

    215 CHURCH STREET NEW HAVEN, CT 06510
    Item 2. 
    (a)Name of person filing:

    Janus Henderson Group Ltd.
    (b)Address or principal business office or, if none, residence:

    201 Bishopsgate EC2M 3AE, United Kingdom
    (c)Citizenship:

    Y9
    (d)Title of class of securities:

    Common Shares
    (e)CUSIP No.:

    G1110E107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Janus Henderson Group Ltd. (JHG) is the ultimate parent of a number of SEC-registered investment advisers and foreign equivalents thereof, including but not limited to Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, Janus Henderson Investors Australia Institutional Funds Management Limited, Janus Henderson Investors Middle East Limited, Janus Henderson Investors (Jersey) Limited, Janus Henderson Investors (Japan) Limited, Janus Henderson Investors (Singapore) Limited, Kapstream Capital Pty Limited, Privacore Capital Advisors LLC, Tabula Investment Management Limited, Victory Park Capital Advisors LLC, and Richard Berstein Advisors LLC (each, an Asset Manager and together, the Asset Managers). The Asset Managers generally exercise investment and/or voting discretion on behalf of their clients which include investment companies, other investment advisers, institutional separate accounts and retail separate accounts (collectively referred to herein as Managed Portfolios). As a result of their exercise of investment and/or voting discretion on behalf of the Managed Portfolios, the Asset Managers may be deemed to be the beneficial owner of 8,584,676 common shares of Biohaven Ltd. However, the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights.
    (b)Percent of class:

    5.7  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    8584676

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    8584676

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Managed Portfolios have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts. Of the Managed Portfolios, none own more than five percent of the common shares of Biohaven Ltd.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Please refer to Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    N/A
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    N/A

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JANUS HENDERSON GROUP Ltd.
     
    Signature:Kristin Mariani
    Name/Title:Head of North America Compliance
    Date:07/08/2026
    Exhibit Information

    Exhibit 24: Power of Attorney Exhibit 99: Item 7

    Get the next $BHVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHVN

    DatePrice TargetRatingAnalyst
    6/29/2026$11.00Neutral → Underperform
    BofA Securities
    4/13/2026$21.00Buy
    Canaccord Genuity
    2/6/2026$23.00Buy
    Goldman
    1/21/2026$22.00Sector Perform → Outperform
    RBC Capital Mkts
    12/3/2025$11.00Buy → Neutral
    H.C. Wainwright
    11/26/2025$11.00Buy → Neutral
    UBS
    11/6/2025$9.00Outperform → Mkt Perform
    Bernstein
    11/5/2025$10.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $BHVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biohaven downgraded by BofA Securities with a new price target

    BofA Securities downgraded Biohaven from Neutral to Underperform and set a new price target of $11.00

    6/29/26 8:54:13 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Biohaven with a new price target

    Canaccord Genuity initiated coverage of Biohaven with a rating of Buy and set a new price target of $21.00

    4/13/26 8:51:07 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Biohaven with a new price target

    Goldman initiated coverage of Biohaven with a rating of Buy and set a new price target of $23.00

    2/6/26 8:10:57 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    SEC Filings

    View All

    Biohaven Ltd. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Biohaven Ltd. (0001935979) (Filer)

    7/9/26 5:11:27 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Biohaven Ltd.

    SCHEDULE 13G/A - Biohaven Ltd. (0001935979) (Subject)

    7/8/26 5:44:00 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Biohaven Ltd. (0001935979) (Filer)

    5/27/26 5:13:33 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Childs John W bought $864,115 worth of shares (28,400 units at $30.43) (SEC Form 4)

    4/A - Biohaven Ltd. (0001935979) (Issuer)

    3/9/26 6:12:05 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VP, Chief Accounting Officer Clark George C. bought $144,770 worth of shares (17,000 units at $8.52) (SEC Form 4)

    4 - Biohaven Ltd. (0001935979) (Issuer)

    11/18/25 7:29:10 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bailey Gregory bought $3,000,000 worth of shares (400,000 units at $7.50), increasing direct ownership by 25% to 2,020,071 units (SEC Form 4)

    4 - Biohaven Ltd. (0001935979) (Issuer)

    11/17/25 7:31:22 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Volles Warren Karl claimed ownership of 248,212 shares (SEC Form 3)

    3 - Biohaven Ltd. (0001935979) (Issuer)

    7/17/26 6:00:13 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mehta Kishan

    4 - Biohaven Ltd. (0001935979) (Issuer)

    4/30/26 8:09:42 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Bailey Gregory

    4 - Biohaven Ltd. (0001935979) (Issuer)

    4/30/26 8:09:11 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

    Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®)Early clinical activity observed: Phase 1 dose-escalation data show early tumor reductions in patients with Fibroblast Growth Factor Receptor (FGFR)3-altered and wild-type overexpressing tumors. Signal activity including confirmed partial responses in heavily pretreated patients in multiple tumor types. Differentiated safety profile: No dose-limiting toxicities and no FGFR inhibitor-class toxicities observed, supporting a potentially broader therapeutic index than approved FGFR tyrosine kinase inhibitors (TKIs).Potential to expand the addressable FGFR3 population

    7/20/26 7:30:00 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Announces Scientific Leadership Transitions

    David Pirman, Ph.D. promoted to Executive Vice President and Head of DiscoveryBruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborationsWarren Volles, General Counsel and Chief Legal Officer, also designated an executive officerNEW HAVEN, Conn., July 9, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) ("Biohaven" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this role, Dr. Pirman will lead the Company's internal drug-discovery organ

    7/9/26 5:00:00 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

    Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-line results on track for 2H 2026Emerging opakalim focal epilepsy and idiopathic generalized epilepsy data presented at recent R&D Day reinforce evidence of target engagement, potential for efficacy, and differentiated tolerability profileIn the ongoing focal epilepsy open-label extension (OLE) study, 54% of participants on opakalim 75 mg once-daily achieved a ≥50% reduction in seizure frequency compared to pre-randomization baseline, with a markedly lower incidence of nervous system adverse events compared to approved and investigational ASMs High double-blind completion rates of ~95%, and high

    6/30/26 7:30:00 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    Financials

    Live finance-specific insights

    View All

    Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

    Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes.Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.Troriluzole achieved statistically significant superiority on 9 consecutive, prespecified primary and secondary endpoints.SCA patients treated with troriluzole showed a 50-70% slowing of disease progression, representing 1.5-2.2 years delay in disease progression over the 3-year study period.Biohaven plans to submit a New Drug Application (NDA)

    9/23/24 7:30:00 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

    Conference call and webcast to be held Monday, September 23, at 8:30am ET  NEW HAVEN, Conn., Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE (NCT06529146), a study designed in discussion with the US Food and Drug Administration (FDA), to assess the effectiveness of troriluzole in Spinocerebellar Ataxia. Conference Call and Webcast DetailsBiohaven will hold a live conference call and webcast Monday, September 23, 2024, at 8:30 a.m. Eastern Time. The live e

    9/20/24 7:09:00 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders

    Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2/JAK3 inhibitorsExclusive license covers global rights excluding China regionBiohaven anticipates initiating Phase 1 clinical development in 2023NEW HAVEN, Conn., March 22, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. BHV-8000 (previously TLL-041) was

    3/22/23 7:30:00 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    3/26/25 7:00:00 AM ET
    $AVTX
    $BHVN
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

    HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

    7/1/24 7:00:00 AM ET
    $BHVN
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments

    Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug AdministrationTaldefgrobep alfa granted Fast Track Designation in SMADriving strong and consistent progress across six robust drug development platforms in 2023:in Kv7 activation, targeting Phase 2/3 study start in focal epilepsy and bipolar disorder in the second half of 2023;Phase 1 study initiation planned with potentially fi

    5/12/23 4:30:00 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

    SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

    11/14/24 3:06:46 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

    SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

    11/12/24 1:20:24 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

    SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

    11/4/24 11:16:33 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care